Integrated Brain and Plasma Dual-channel Metabolomics to Explore the Treatment Effects of Alpinia OxyphyllaFructus on Alzheimer's Disease

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Aug 8

PMID 37552694

Authors

Zhi Sun

Yuanyuan Zhang

Mengya Zhang

Shengnan Zhou

Wenbo Cheng

Lianping Xue

Peipei Zhou

Xiaojing Li

Zhibo Zhang

Lihua Zuo

Affiliations

Soon will be listed here.

Abstract

Alpinia oxyphylla Fructus, called Yizhi in Chinese, is the dried fruit of Alpinia oxyphylla Miquel. It has been used in traditional Chinese medicine to treat dementia and memory defects of Alzheimer's disease for many years. However, the underlying mechanism is still unclear. In this study, we used a rat Alzheimer's disease model on intrahippocampal injection of aggregated Aβ1-42 to study the effects of Alpinia oxyphylla Fructus. A brain and plasma dual-channel metabolomics approach combined with multivariate statistical analysis was further performed to determine the effects of Alpinia oxyphylla Fructus on Alzheimer's disease animals. As a result, in the Morris water maze test, Alpinia oxyphylla Fructus had a clear ability to ameliorate the impaired learning and memory of Alzheimer's disease rats. 11 differential biomarkers were detected in AD rats' brains. The compounds mainly included amino acids and phospholipids; after Alpinia oxyphylla Fructus administration, 9 regulated biomarkers were detected compared with the AD model group. In the plasma of AD rats, 29 differential biomarkers, primarily amino acids, phospholipids and fatty acids, were identified; After administration, 23 regulated biomarkers were detected. The metabolic pathways of regulated metabolites suggest that Alpinia oxyphylla Fructus ameliorates memory and learning deficits in AD rats principally by regulating amino acid metabolism, lipids metabolism, and energy metabolism. In conclusion, our results confirm and enhance our current understanding of the therapeutic effects of Alpinia oxyphylla Fructus on Alzheimer's disease. Meanwhile, our work provides new insight into the potential intervention mechanism of Alpinia oxyphylla Fructus for Alzheimer's disease treatment.

Citing Articles

Recent Research Progress on the Chemical Constituents, Pharmacology, and Pharmacokinetics of Fructus.

Liao J, Zhao X Molecules. 2024; 29(16).

PMID: 39202984 PMC: 11357166. DOI: 10.3390/molecules29163905.

References

Soria Lopez J, Gonzalez H, Leger G . Alzheimer's disease. Handb Clin Neurol. 2019; 167:231-255. DOI: 10.1016/B978-0-12-804766-8.00013-3. View

Jones L, McDonald D, Borum P . Acylcarnitines: role in brain. Prog Lipid Res. 2009; 49(1):61-75. DOI: 10.1016/j.plipres.2009.08.004. View

Ma Y, Li Y, Zong L, Xing X, Zhang W, Cao Y . Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response. Brain Res. 2011; 1400:112-24. DOI: 10.1016/j.brainres.2011.05.030. View

Shi S, Zhao X, Liu B, Li H, Liu A, Wu B . The effects of sesquiterpenes-rich extract of Alpinia oxyphylla Miq. on amyloid-β-induced cognitive impairment and neuronal abnormalities in the cortex and hippocampus of mice. Oxid Med Cell Longev. 2014; 2014:451802. PMC: 4142297. DOI: 10.1155/2014/451802. View

Fonteh A, Harrington R, Tsai A, Liao P, Harrington M . Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2006; 32(2):213-24. DOI: 10.1007/s00726-006-0409-8. View

Zhang Q, Zheng Y, Hu X, Hu X, Lv W, Lv D . Ethnopharmacological uses, phytochemistry, biological activities, and therapeutic applications of Alpinia oxyphylla Miquel: A review. J Ethnopharmacol. 2018; 224:149-168. DOI: 10.1016/j.jep.2018.05.002. View

Paul V, Reddy L, Ekambaram P . A reversal by L-arginine and sodium nitroprusside of ageing-induced memory impairment in rats by increasing nitric oxide concentration in the hippocampus. Indian J Physiol Pharmacol. 2005; 49(2):179-86. View

Lin S, Liu H, Kanawati B, Liu L, Dong J, Li M . Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer's disease in CRND8 mice. Anal Bioanal Chem. 2013; 405(15):5105-17. DOI: 10.1007/s00216-013-6825-1. View

Gong Y, Liu Y, Zhou L, Di X, Li W, Li Q . A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model. J Pharm Biomed Anal. 2015; 115:174-82. DOI: 10.1016/j.jpba.2015.07.007. View

10.

Choi S, DiSilvio B, Fernstrom M, Fernstrom J . Oral branched-chain amino acid supplements that reduce brain serotonin during exercise in rats also lower brain catecholamines. Amino Acids. 2013; 45(5):1133-42. DOI: 10.1007/s00726-013-1566-1. View

11.

Bezprozvanny I, Mattson M . Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008; 31(9):454-63. PMC: 2566585. DOI: 10.1016/j.tins.2008.06.005. View

12.

Evans J, Ko Y, Mata W, Saquib M, Eldridge J, Cohen-Gadol A . Arachidonic acid induces brain endothelial cell apoptosis via p38-MAPK and intracellular calcium signaling. Microvasc Res. 2014; 98:145-58. DOI: 10.1016/j.mvr.2014.04.011. View

13.

Ibanez C, Simo C, Martin-Alvarez P, Kivipelto M, Winblad B, Cedazo-Minguez A . Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem. 2012; 84(20):8532-40. DOI: 10.1021/ac301243k. View

14.

Sanchez-Mejia R, Mucke L . Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta. 2010; 1801(8):784-90. PMC: 3024142. DOI: 10.1016/j.bbalip.2010.05.013. View

15.

Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View

16.

Liu A, Zhao X, Li H, Liu Z, Liu B, Mao X . 5-Hydroxymethylfurfural, an antioxidant agent from Alpinia oxyphylla Miq. improves cognitive impairment in Aβ 1-42 mouse model of Alzheimer's disease. Int Immunopharmacol. 2014; 23(2):719-25. DOI: 10.1016/j.intimp.2014.10.028. View

17.

Bubber P, Hartounian V, Gibson G, Blass J . Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients. Eur Neuropsychopharmacol. 2010; 21(3):254-60. PMC: 3033969. DOI: 10.1016/j.euroneuro.2010.10.007. View

18.

Kerner J, Hoppel C . Fatty acid import into mitochondria. Biochim Biophys Acta. 2000; 1486(1):1-17. DOI: 10.1016/s1388-1981(00)00044-5. View

19.

Martin S, Brash A, Murphy R . The discovery and early structural studies of arachidonic acid. J Lipid Res. 2016; 57(7):1126-32. PMC: 4918860. DOI: 10.1194/jlr.R068072. View

20.

Fontani G, Corradeschi F, Felici A, Alfatti F, Migliorini S, Lodi L . Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest. 2005; 35(11):691-9. DOI: 10.1111/j.1365-2362.2005.01570.x. View